Top 122 Cancer Immunotherapy startups
Oct 23, 2024 | By Jason Kwon | 28 |
These startup develop cancer immunotherapy treatments that boost own body's natural defenses (immune system resources) to fight the cancer.
1
Country: USA | Funding: $244.3M
Xilio Therapeutics is a biopharmaceutical company focused on developing highly-potent, targeted immuno-oncology therapeutics.
Xilio Therapeutics is a biopharmaceutical company focused on developing highly-potent, targeted immuno-oncology therapeutics.
2
Country: USA | Funding: $112M
AvenCell Therapeutics develops next generation immunotherapies for hard-to-treat cancers.
AvenCell Therapeutics develops next generation immunotherapies for hard-to-treat cancers.
3
Country: Switzerland | Funding: $101.8M
ImmunOs Therapeutics AG is a clinical-stage biotechnology company focused on discovering and developing next generation and novel human immunomodulatory proteins with a role in both innate and adaptive immunity.Their mission is to develop the next generation of novel therapeutics that will improve the lives of patients with serious disease.
ImmunOs Therapeutics AG is a clinical-stage biotechnology company focused on discovering and developing next generation and novel human immunomodulatory proteins with a role in both innate and adaptive immunity.Their mission is to develop the next generation of novel therapeutics that will improve the lives of patients with serious disease.
4
Country: UK | Funding: $50M
Enara Bio offers targeted cancer immunotherapies. It is leveraging its platform to discover therapies for ovarian cancer and other solid tumors.
Enara Bio offers targeted cancer immunotherapies. It is leveraging its platform to discover therapies for ovarian cancer and other solid tumors.
5
Country: USA | Funding: $3.9B
At Moderna, we are pioneering the development of a new class of drugs made of messenger RNA (mRNA). This novel drug platform builds on the discovery that modified mRNA can direct the body’s cellular machinery to produce nearly any protein of interest, from native proteins to antibodies and other entirely novel protein constructs that can have therapeutic activity inside and outside of cells.
At Moderna, we are pioneering the development of a new class of drugs made of messenger RNA (mRNA). This novel drug platform builds on the discovery that modified mRNA can direct the body’s cellular machinery to produce nearly any protein of interest, from native proteins to antibodies and other entirely novel protein constructs that can have therapeutic activity inside and outside of cells.
6
Country: USA | Funding: $1.1B
Kymera Therapeutics is a biotechnology company that specializes in the field of targeted protein degradation.
Kymera Therapeutics is a biotechnology company that specializes in the field of targeted protein degradation.
7
Country: Germany | Funding: $1.9B
We are developing the next generation of personalized immunotherapies to help revolutionize the treatment of people with cancer and other debilitating diseases.
We are developing the next generation of personalized immunotherapies to help revolutionize the treatment of people with cancer and other debilitating diseases.
8
Country: USA | Funding: $1.6B
IOVANCE Biotherapeutics is focused on the development and commercialization of autologous cellular immunotherapies optimizing personalized, tumor-directed Tumor Infiltrating Lymphocytes (TIL)
IOVANCE Biotherapeutics is focused on the development and commercialization of autologous cellular immunotherapies optimizing personalized, tumor-directed Tumor Infiltrating Lymphocytes (TIL)
9
Country: USA | Funding: $1.3B
Fate Therapeutics is a stem cell and developmental biology research company using biological mechanisms to develop stem cell therapeutics.
Fate Therapeutics is a stem cell and developmental biology research company using biological mechanisms to develop stem cell therapeutics.
10
Country: USA | Funding: $1.1B
ImmunityBio is a privately held immunotherapy company with one of the broadest portfolios of biological molecules spanning albumin-linked chemotherapeutic, peptides, fusion proteins, cytokine, monoclonal antibodies, adenovirus and yeast vaccine therapies.
ImmunityBio is a privately held immunotherapy company with one of the broadest portfolios of biological molecules spanning albumin-linked chemotherapeutic, peptides, fusion proteins, cytokine, monoclonal antibodies, adenovirus and yeast vaccine therapies.
11
Country: UK | Funding: $1.1B
Bicycle Therapeutics is developing a technology for the creation of new generation biotherapeutics.
Bicycle Therapeutics is developing a technology for the creation of new generation biotherapeutics.
12
Country: UK | Funding: $1.1B
Autolus utilises advanced cell programming CAR-T and manufacturing technologies and we have established a development-stage pipeline of products for the treatment of haematological malignancies and solid tumours.
Autolus utilises advanced cell programming CAR-T and manufacturing technologies and we have established a development-stage pipeline of products for the treatment of haematological malignancies and solid tumours.
13
Country: USA | Funding: $967.1M
Arcus discovers and develops innovative cancer immunotherapies based on known but under-exploited biology. Arcus’s lead program targets the adenosine pathway, which has been shown to play a significant role in driving immuno-suppression in the tumor micro-environment.
Arcus discovers and develops innovative cancer immunotherapies based on known but under-exploited biology. Arcus’s lead program targets the adenosine pathway, which has been shown to play a significant role in driving immuno-suppression in the tumor micro-environment.
14
Country: USA | Funding: $917.7M
Using our proprietary Antibody-Coupled T-cell Receptor (ACTR) technology, we are discovering and developing new cellular immunotherapies for cancer. The company doesn’t intend to make its own antibodies in-house, but rather align with various companies that want to enhance their experimental antibody drugs.
Using our proprietary Antibody-Coupled T-cell Receptor (ACTR) technology, we are discovering and developing new cellular immunotherapies for cancer. The company doesn’t intend to make its own antibodies in-house, but rather align with various companies that want to enhance their experimental antibody drugs.
15
Country: Switzerland | Funding: $751.6M
ADC Therapeutics is focused on the development of proprietary Antibody Drug Conjugates (ADCs) for the treatment of both solid and hematological cancers. ADC Therapeutics employs monoclonal antibodies specific to particular tumor antigens conjugated to a novel class of highly potent pyrrolobenzodiazepine (PBD) -based warheads to selectively kill cancer cells.
ADC Therapeutics is focused on the development of proprietary Antibody Drug Conjugates (ADCs) for the treatment of both solid and hematological cancers. ADC Therapeutics employs monoclonal antibodies specific to particular tumor antigens conjugated to a novel class of highly potent pyrrolobenzodiazepine (PBD) -based warheads to selectively kill cancer cells.
16
Country: China | Funding: $737.6M
Rakuten Aspyrian is developing tumor-targeted precision therapies based on its proprietary platform Photoimmunotherapy.
Rakuten Aspyrian is developing tumor-targeted precision therapies based on its proprietary platform Photoimmunotherapy.
17
Country: USA | Funding: $694.1M
IDEAYA is an oncology-focused biotechnology company committed to the discovery of breakthrough synthetic lethality medicines for genetically defined patient populations and immuno-oncology therapies targeting immuno-metabolism and innate immunity.
IDEAYA is an oncology-focused biotechnology company committed to the discovery of breakthrough synthetic lethality medicines for genetically defined patient populations and immuno-oncology therapies targeting immuno-metabolism and innate immunity.
18
Country: USA | Funding: $652M
Apogee Therapeutics operates pipeline candidates designed to treat inflammatory and immunological disorders.
Apogee Therapeutics operates pipeline candidates designed to treat inflammatory and immunological disorders.
19
Country: USA | Funding: $548.9M
Janux Therapeutics develops immunotherapies that generates immune responses to prevent tumors and not affecting a patient’s healthy tissue.
Janux Therapeutics develops immunotherapies that generates immune responses to prevent tumors and not affecting a patient’s healthy tissue.
20
Country: USA | Funding: $545.9M
Nurix develops small molecule inhibitors for the treatment of proliferative and degenerative diseases.
Nurix develops small molecule inhibitors for the treatment of proliferative and degenerative diseases.